1. Introduction {#sec1}
===============

Pituitary stalk interruption syndrome (PSIS) is a rare congenital defect with an estimated incidence of 0.5/100,000 births. PSIS causes various symptoms of pituitary hormone deficiency, including growth retardation and infertility \[[@B1]--[@B3]\].

Previous studies have revealed that genetic changes may contribute to its etiology. Studies on patients born to consanguineous parents have revealed germline mutations in some genes that may be responsible for the disease. For example, Fernandez-Rodriguez et al. reported a homozygous mutation, 301-302delAG, in the *PROP1* gene in two consanguineous sisters \[[@B4]\]. Reynaud et al. identified a novel *PROKR2* variant (p.Ala51Thr) in two familial cases \[[@B1]\]. In addition, Tatsi et al. \[[@B5]\] found a novel heterozygous nonsense mutation (c.799C \> T, p.Q267X) in the *TGIF* gene in a female PSIS patient with a single central incisor; her father had the same mutation but was asymptomatic.

However, the above studies only provide partial details of the genetic variants responsible, as the samples were limited to siblings or one parent. In our study, we examined DNA from a PSIS boy, his unaffected parents, and his sister. We hope that our findings help in obtaining more information about this rare disease. Moreover, we performed functional verification of a novel gene found by sequencing to explain the pathogenesis in-depth.

2. Materials and Methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

A boy with PSIS was referred to Chinese PLA General Hospital; all his family members, including his unaffected sister and healthy parents, were also included. The study was approved by the Ethics Committee of the General Hospital of Chinese PLA, and informed consent was obtained from all participants prior to their participation in the study. The family lineage is displayed in [Figure 1](#fig1){ref-type="fig"}.

2.2. Whole-Genome Sequencing and Analysis {#sec2.2}
-----------------------------------------

Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) from the family members in our discovery cohort. Exome capturing was performed to collect whole exons of human genomic DNA. The exon-enriched DNA libraries were sequenced in 100 bp paired-end reads using a HiSeq2000 sequencer (Illumina, San Diego, CA); coverage of 100x was typically achieved for each sample.

Qualified DNA was randomly fragmented using a Covaris Ultrasonic Processor. DNA libraries were constructed through end repair, addition of A to tails, purification, and PCR amplification. The pair-end libraries were sequenced using an Illumina HiSeq X Ten machine.

2.3. Genome Sequencing and Analysis {#sec2.3}
-----------------------------------

After verification, the different libraries were sequenced based on the effective concentration and required raw data by Illumina HiSeq X Ten sequencing platform after being verified. Clean reads were obtained after removing adaptor sequences and low mapping quality reads. Read alignment to the reference genome hg38 was performed with Burrows--Wheeler Aligner MEM (BWA-MEM) (0.7.15). Duplicated reads were marked and removed by Picard (2.5.0). The alignment results were sorted using SAMtools (0.1.18). Recalibration of base quality scores and local realignment around InDELs were performed using Genome Analysis Toolkit (GATK) (3.6) \[[@B6]\]. SNVs and InDELs for each sample were determined using GATK HaplotypeCaller. Structural variants (SVs) were evaluated via LUMPY \[[@B7]\]. The database annotation, analysis, and global overview of variation were performed by ANNOVAR \[[@B8]\] and Variant Effect Predictor \[[@B9]\]. The genes *SOX3*, *PROP1*, *LHX3*, *LHX4*, *HESX1*, *OTX2*, *PROKR2*, *TGIF*, *GPR161*, and *CDON* have been analyzed in gene variation sets \[[@B1], [@B2], [@B10]--[@B13]\].

2.4. Sanger Sequencing {#sec2.4}
----------------------

Candidate variants were further confirmed by Sanger sequencing executed by Taihegene Biotechnology (Beijing). Purified PCR amplification products were obtained after amplification of target gene fragments in DNA samples using a Biometra PCR instrument. Chromas 2 software was used for manual interpretation, and sequences were obtained from NCBI GenBank (<http://www.ncbi.nlm.nih.gov/sites/entrez/>). The first-generation sequencing results were compared with the second-generation sequencing results, and genes were screened for functional verification. The primer sequences are shown in [Table 1](#tab1){ref-type="table"}.

2.5. Functional Verification {#sec2.5}
----------------------------

### 2.5.1. Cell Culture and Transfection {#sec2.5.1}

Human embryonic stem cell (HESCS) H1 cells were cultured in mTeSR1 medium in pretreated culture plates covered with Matrigel (BD Company). The cells were passaged at approximately 70% confluence. siRNAs targeting *MUC12*, *NBPF9*, and *TYW1B* were designed by Gemma Company. Transfection was based on optimization methods reported in domestic and foreign literature \[[@B14]--[@B16]\]. For further experiments, RNA was extracted at 24 h after transfection and protein at 48 h after transfection.

### 2.5.2. Western Blotting {#sec2.5.2}

Protein samples were boiled (5 min, 95°C), separated by SDS-PAGE, and transferred onto polyvinylidene difluoride membranes. The membranes were blocked for 1 h in 5% bovine serum albumin (BSA) in TBST (20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween 20). Primary antibodies against LHX3 and PITX1 (Enogene Biotech, Nanjing, China) were diluted in TBST containing 5% BSA and then applied to the membranes overnight at 4°C at a dilution of 1 : 1,000. After being washed three times with TBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. The membranes were washed three times with TBST and developed with Chemiluminescence ECL Plus-Western Blotting detection reagents (Amersham Biosciences, Piscataway, NJ, USA).

3. Results {#sec3}
==========

3.1. Clinical Features {#sec3.1}
----------------------

The boy with PSIS was referred to our hospital due to growth retardation. He was born in a nonconsanguineous family, and none of his relatives had a history of growth retardation or short stature. He was born via breech delivery with a body weight of 3,200 g and a height of 50 cm. After he was 5 years old, his parents noticed growth retardation compared with other children of his age. When he was then admitted to a local children\'s hospital, his height was 100 cm (−2.15 SDS), and he showed a delayed bone age of 3. According to GH stimulation tests, the maximum value detected at the time was 0.69 ng/mL, along with a low IGF-1 level estimated at 24.45 ng/mL. Pituitary CT revealed a hypoplastic pituitary gland. He was diagnosed with GH deficiency, and hormone replacement therapy was initiated.

In 2013, when the boy was 8 years old, he was admitted to Chinese PLA General Hospital; his height was 106 cm (−1.07 SDS), and he had a body weight of 16.5 kg. He had a single central incisor, sharp palate, and single transverse palmar crease; he could not easily bend the fourth and fifth fingers of both hands. In addition to GH deficiency, he was diagnosed with hypothyroidism (free T4: 8.35 pmol/mL (reference interval: 12--22 pmol/mL); TSH: 6.54 mU/L (reference interval: 0.35--5.5 mU/L)) and hypoadrenalism (F 8 am: 128.6 nmol/L (reference interval: 198.7--797.5 nmol/L at 24 h UFC) at admission. His bone age was that of a 5-year-old boy. The patient was treated with GH, hydrocortisone, and levothyroxine thereafter. Records from the latest follow-up in 2015 showed a height of 131 cm (−1.06 SDS) and a bone age of approximately 8 years.

His younger sister, who was the second child in this family, exhibited normal growth with no deformities. As a 5-year-old girl, her height was 111.5 cm and her weight was 18 kg, which were in the normal range for her age. The results of her hormone laboratory tests were normal. The boy\'s parents denied consanguineous marriage or family histories of similar manifestations. The mother confirmed that she did not receive radiation or take any drugs during pregnancy. [Figure 2](#fig2){ref-type="fig"} shows the appearance of the PSIS boy and his healthy sister.

3.2. Molecular and *In Silico* Findings {#sec3.2}
---------------------------------------

### 3.2.1. Variant Statistics {#sec3.2.1}

*(1) SNVs and InDELs*. We obtained 4,935,685 SNVs from the four samples as well as 9.644 InDELs; based on genetics, genomic region, and functional annotation, we filtered SNV results for each sample. 48.1% were intron variants and 37.7% were intergenic variants. In exon region, 52.3% were synonymous variants.

*(2) Structural Variation (SV)*. LUMPY and the DGV database were used to assess all SVs in the 4 samples, SVs were detected in different regions of the genomic region, and 97.06% SVs were located in intergenic region.

### 3.2.2. Analysis of Reported Genes {#sec3.2.2}

Mutations in the genes *SOX3, PROP1*, *LHX3*, *LHX4*, *HESX1*, *OTX2*, *PROKR2*, *TGIF*, *GPR161*, and *CDON* have been reported. The current database is not related to PSIS mutation locus information matching, according to the variation function for filtering exonic regions of the mutation loci. There are five genes that showed regional variation, including *LHX4*, *PROP1*, *CDON*, *TGIF1*, and *PROKR2*, as shown in [Table 2](#tab2){ref-type="table"}.

3.3. De Novo Mutation Analysis {#sec3.3}
------------------------------

We aimed to find mutations that manifested as hybrid-type genome mutation loci in the PSIS boy but not genomic mutations in his parents. A total of 19 specific mutations were found ([Table 3](#tab3){ref-type="table"}).

3.4. Inheritance Pattern Analysis {#sec3.4}
---------------------------------

According to the pedigree information of the family, the variation and variation annotation information for each individual were used for grade selection; mutation loci were filtered by grade and function (nonsynonymous mutations) to obtain 267 candidate mutation loci. The 267 variation sites are located in 207 genes. Further analysis was performed by dbSNP, ClinVar, Exome Sequencing Project, 1000 Genomes Project, and Exome Aggregation Consortium database. [Table 4](#tab4){ref-type="table"} presents 11 filtered recessive genetic variations.

As most of the above genes have rarely been studied, we selected *NBPF9*, *MUC12*, and *TYW1B* as candidate genes to further analyze their roles in nervous system development and cancer \[[@B17], [@B18]\].

3.5. Sanger Sequencing {#sec3.5}
----------------------

We further confirmed the candidate variations by Sanger sequencing, and the results are depicted in [Figure 3](#fig3){ref-type="fig"}.

3.6. Protein Structure Prediction {#sec3.6}
---------------------------------

After protein structure prediction, it was found that the NBPF9 p.L279W point mutation would cause protein structure variation. The conserved amino acid sequence is illustrated in [Figure 4](#fig4){ref-type="fig"}. This sequence shows good conservation.

3.7. Cell Culture and Western Blotting {#sec3.7}
--------------------------------------

[Figure 5](#fig5){ref-type="fig"} shows the cell culture of HESCS (H1 cells). siRNAs targeting the candidate genes *NBPF9*, *MUC12*, and *TYW1B* were transfected into cells, and inhibition rates of more than 50% were obtained with the NBPF9 and MUC12 groups. At the protein level, LHX3 abundance decreased after transfection with *NBPF9* siRNA. For PITX1, no significant change was observed between the *NBPF9* transfection group and the control group.

4. Discussion {#sec4}
=============

As a rare and complicated defect, PSIS is thought to be caused by genetic changes. However, genetic variants are found in only 5% of cases. Sporadic cases have been collected and studied, but little information was found. Through familial cases, we obtained some reported mutations, but in these studies, only the father or mother\'s DNA was examined. Here, we evaluate a family with a PSIS boy and a healthy sibling and parents, which may reveal more details of the etiology of PSIS.

We analyzed the reported genes *LHX4*, *PROP1*, *CDON*, *TGIF*, and *PROKR2* in our study. LHX4/LHX3 are members of the LIM-homeobox family and regulate the proliferation and differentiation of pituitary lineages \[[@B1], [@B2], [@B12]\]. PROP1 is involved in early patterning, proliferation, positional determination, and terminal differentiation of the pituitary gland \[[@B4], [@B13]\]. CDON is a component of a cell-surface receptor complex that mediates cell-cell interactions between muscle precursor cells \[[@B11]\]. Tatsi reported TGIF as an active transcriptional corepressor of *SMAD2* that may participate in the transmission of nuclear signals during development and in adults \[[@B5]\]. PROKR2 is thought to be involved in endocrine angiogenesis and neuronal migration and is expressed in the hypothalamus and pituitary gland \[[@B1]\]. However, none of the mutation frequencies were significant. In other words, the mutation frequencies were equal to those of the healthy group. We further performed inheritance pattern analysis and found 11 genes with related variations but that have rarely been studied; thus, little is known about their functions.

In our previous study related to sporadic cases, we proposed that compromised genetic interactions among multiple signaling pathways are likely to underlie the pathogenesis of sporadic PSIS \[[@B19]\]. Therefore, multigenetic causes may explain the pathogenesis of PSIS. Therefore, in this study, we attempted to identify novel gene variations. After bioinformatics analysis, we selected candidate variants for further research.

NBPF9 belongs to the neuroblastoma breakpoint family (NBPF) family, the members of which are characterized by binding to the repetitive DUF1220 protein domain. Gene copy number variation exists in the region of human chromosome 1q21. 1. DUF1220 domains have been associated with many diseases related to development and neurogenesis, such as small head deformity, autism and schizophrenia, mental retardation, congenital heart disease, neuroblastoma, and congenital kidney and urinary tract abnormalities, and previous studies have reported that DUF1220 is associated with lung cancer \[[@B17]\].

We found that the level of LHX3 decreased after transfection with *NBPF9* siRNA. The *LHX3* and *PITX1* genes appear to play important roles during pituitary development. LHX3 is a LIM homologous domain transcription factor that is one of the earliest pituitary transcription factors expressed in development; it determines the specific differentiation of tissues and cells in vertebrates and invertebrates by regulating the expression of some genes. Currently, three types of *LHX3* autosomal recessive inheritance have been identified in humans, and all patients have multiple pituitary hormone deficiencies \[[@B21]--[@B23]\]. *PITX1*, a member of the homologous domain protein transcription factor (PITX) family, was found in fruit flies in 1996; the encoded protein activates the transcription of opioid melanocortin precursor and is involved in the derivation and development of the pituitary gland \[[@B24]\]. The above research results indicate that LHX3 plays an important role in the development of the pituitary; in contrast, the *NBPF9* gene has only been shown to be an important link in pituitary development.

In our study, we describe the landscape of the gene spectrum of a PSIS family and, based on further experiments, speculate that the *NBPF9* gene is likely a regulatory factor affecting the development of the pituitary. Nonetheless, more samples of entire PSIS families are needed to explain the exact pathogenesis.

5. Conclusions {#sec5}
==============

The findings of this study provide considerable information about the gene spectrum of PSIS as a rare disease. However, there is a lack of evidence regarding all of the reported genes. More samples are needed to assess clinical applicability. The *NBPF9* gene may be involved in congenital hypopituitarism \[[@B20]\].
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![Pedigree of this family.](IJE2020-5401738.001){#fig1}

![The PSIS boy and his healthy sibling. The left is the PSIS boy (8 years old), and his healthy sister (5 years old) was on the right.](IJE2020-5401738.002){#fig2}

![Mutations in the *NBPF9* gene and Sanger sequencing validation.](IJE2020-5401738.003){#fig3}

![Structure of the protein encoded by the *NBPF9* gene. (a). Structure of the protein encoded by the *NBPF9* gene, which would cause protein structure variation. (b). Conserved sequence in the region of the NBPF9 p.L279W mutation.](IJE2020-5401738.004){#fig4}

![Culture status of human embryonic stem cells, siRNA transfection effect, and target gene expression. (a) Human embryonic stem cells on the left showed scattered growth and human embryonic stem cells on the right gradually formed cell colonies. (b) Cells after transfection under a fluorescence microscope. (c) siRNA transfection after 24 h, with efficiency above 60%. qPCR results after silencing the expression of each gene are shown below to verify the inhibitory effect. (d) Expression of LHX3 and PITX1 by western blotting, in which LHX3 was significantly decreased after treatment with siRNA targeting *NBPF9*.](IJE2020-5401738.005){#fig5}

###### 

Primer sequences.

  --------------------------------------------
  Gene      Primer sequence (5′-3′)
  --------- ----------------------------------
  FCGBP     F: 5′-AACgAggggTgAggTTCTTAC3′\
            R: 5′-CCACCACAAAACATCCTTTTCA-3″

  RANGAP1   F: 5′-gAgACAACCAAAggAAgCCTgT-3′\
            R: 5′-CAgAgACATgAAggAggggAgT-3′

  FAM155A   F: 5′-CAggCCTggAATTTgCTTTTAT-3′\
            R: 5′-gTTgCAgTAAggCAAgAgATCg-3′

  EPHA6     F: 5′-ATCTCAggACAgTTCCTATTC-3′\
            R: 5′-TTTTTCTgCAgCCCCggCTgTg-3′

  AGAP9     F: 5′-TgCTCTACCAAgTCTggTCTgC-3′\
            R: 5′-ATgTCATggAAAAAgTCgAgCA-3″

  NBPF9     F: 5′-CACTTgTACCCAggAgCCAgAg-3′\
            R: 5′-TggggACTAgACATCCCAgTCT-3′

  TYW1B     F: 5′-gCTCTCCTTgTTgAATTgAT-3′\
            R: 5′-TgCATCAACTAATgggTgAAA-3′

  MUC12     F: 5′-ACCAAgCCTCAgTgAgAAATC-3′\
            R: 5′-ggACAgTgCTgTgTCAgTTg-3′
  --------------------------------------------

###### 

Analysis of reported genes.

  Pos      Gene     Chr   Start       End         Ref   Alt   Type
  -------- -------- ----- ----------- ----------- ----- ----- -------------------
  Exonic   LHX4     1     180230592   180230592   T     C     Synonymous SNV
  Exonic   LHX4     1     180274389   180274389   A     G     Nonsynonymous SNV
  Exonic   PROP1    5     177995875   177995875   T     C     Nonsynonymous SNV
  Exonic   PROP1    5     177995907   177995907   A     G     Synonymous SNV
  Exonic   CDON     11    125961075   125961075   A     T     Nonsynonymous SNV
  Exonic   CDON     11    125978366   125978366   C     T     Synonymous SNV
  Exonic   CDON     11    126021374   126021374   C     T     Nonsynonymous SNV
  Exonic   TGIF     18    3457541     3457541     A     G     Synonymous SNV
  Exonic   TGIF1    18    3457609     3457609     C     T     Nonsynonymous SNV
  Exonic   PROKR2   20    5302073     5302073     G     T     Synonymous SNV
  Exonic   PROKR2   20    5302085     5302085     G     A     Synonymous SNV
  Exonic   PROKR2   20    5302204     5302204     C     T     Nonsynonymous SNV
  Exonic   PROKR2   20    5302610     5302610     C     G     Synonymous SNV
  Exonic   PROKR2   20    5302730     5302730     G     A     Synonymous SNV

###### 

Specific mutations in the PSIS boy.

  Pos       Gene      Chr     Start       End         Ref            Alt   Type
  --------- --------- ------- ----------- ----------- -------------- ----- ------------------------
  Exonic    TRIOBP    chr22   37724147    37724147    G              A     Nonsynonymous SNV
  Exonic    GP1BA     chr17   4933823     4933900     AGC......CCC   ---   Nonframeshift deletion
  Exonic    FCGBP     chr19   39902043    39902043    A              G     Nonsynonymous SNV
  Exonic    RANGAP1   chr22   41254465    41254467    TCC            ---   Nonframeshift deletion
  Exonic    POTEG     chr14   19433854    19433854    C              T     Nonsynonymous SNV
  Exonic    DNAJB6    chr7    157385630   157385630   G              A     Nonsynonymous SNV
  Exonic    FAM155A   chr13   107866364   107866365   TG             ---   Frameshift deletion
  Exonic    FAM155A   chr13   107866367   107866379   CGC......GCT   ---   Frameshift deletion
  Exonic    GAGE2A,   chrx    49590729    49590729    C              T     Nonsynonymous SNV
  GAGE2B,                                                                  
  GAGE2C                                                                   
  Exonic    EPHA6     chr3    96814795    96814797    GAG            ---   Nonframeshift deletion
  Exonic    FCGBP     chr19   39902109    39902109    T              G     Nonsynonymous SNV
  Exonic    TAL1      chr1    47219924    47219925    AG             ---   Frameshift deletion
  Exonic    FLG       chr1    152312347   152312347   A              G     Nonsynonymous SNV
  Exonic    MUC12     chr7    100997864   100997864   G              A     Nonsynonymous SNV
  Exonic    RASA4B    chr7    102485138   102485138   C              T     Nonsynonymous SNV
  Exonic    AGAP9     chr10   47502991    47502991    C              T     Nonsynonymous SNV
  Exonic    ZNF705E   chr11   71818808    71818808    T              C     Nonsynonymous SNV
  Exonic    NPIPB11   chr16   29383805    29383805    C              T     Nonsynonymous SNV
  Exonic    ZNF705E   chr11   71818809    71818809    G              A     Stop-gain

###### 

Inheritance pattern analysis.

  Gene          Chr     Start       End         Ref   Alt   Type
  ------------- ------- ----------- ----------- ----- ----- -------------------
  *SPATA31A3*   chr9    66987043    66987043    G     T     Nonsynonymous SNV
  *OR9I1*       chr11   58118963    58118963    G     T     Nonsynonymous SNV
  *ABCB11*      chr2    168944621   168944621   G     A     Nonsynonymous SNV
  *AGAP9*       chr10   47503470    47503470    G     A     Nonsynonymous SNV
  *TYW1B*       chr7    72728896    72728896    C     T     Stop-gain
  *AGAP9*       chr10   47502579    47502579    C     T     Nonsynonymous SNV
  *AGAP9*       chr10   47502650    47502650    G     C     Nonsynonymous SNV
  *NBPF9*       chr1    149075807   149075807   A     C     Nonsynonymous SNV
  *AGAP9*       chr10   47502343    47502343    T     C     Nonsynonymous SNV
  *AGAP9*       chr10   47502604    47502604    A     G     Nonsynonymous SNV
  *ZNF180*      chr19   44497294    44497294    A     G     Nonsynonymous SNV
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